In vitro and in vivo antitumor effects of 50 to 100‑KDa components from B16 melanoma culture supernatant

Qin,Ying‑Song; Zhang,Xu; Zhang,Xiang‑Yu

doi:10.3892/ol.2015.3239

In vitro and in vivo antitumor effects of 50 to 100‑KDa components from B16 melanoma culture supernatant

Authors:
- Ying‑Song Qin
- Xu Zhang
- Xiang‑Yu Zhang
View Affiliations

Affiliations: Department of Pathophysiology, Xuzhou Medical College, Xuzhou, Jiangsu, P.R. China, Department of Otolaryngological, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, P.R. China, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China
Published online on: May 20, 2015 https://doi.org/10.3892/ol.2015.3239
Pages: 149-155
Copyright: © Qin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The development of immunological therapies for melanoma has been of considerable concern in recent years. Whole tumor cell lysates have been used to develop antitumor vaccines, but the effective components of the lysates have not been identified. In the present study, protein elements were purified from the B16 supernatant to analyze the in vitro chemotaxis towards mouse spleen lymphocytes using a Boyden chamber. Prior to establishing a B16 melanoma model, C57BL/6 mice were vaccinated with these proteins, and melanoma growth, tumor appearance time and behavioral changes were observed. Next, the cytotoxicity and subsets of the tumor infiltrating lymphocytes, and the histological characteristics of the melanoma were analyzed. The isolated purified fragments of B16 melanoma culture supernatant had strong antitumor effects. The possible antitumor mechanism was delineated, and was identified to possibly be through the activation of cluster of differentiation 8‑positive T cells and the promotion of B16 cell differentiation. These methods will provide a novel insight into understanding antitumor immunological mechanisms and provide a potential avenue for immunotherapy.

View Figures

View References

1	Gyorki DE, Callahan M, Wolchok JD and Ariyan CE: The delicate balance of melanoma immunotherapy. Clin Transl Immunology. 2:e52013. View Article : Google Scholar : PubMed/NCBI
2	Yee C, Thompson J, Byrd D, et al: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 99:16168–16173. 2002. View Article : Google Scholar : PubMed/NCBI
3	Cui NP, XIE SJ, Han JS, et al: Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice. Chin Med J (Engl). 125:794–800. 2012.PubMed/NCBI
4	Chiu HY, Sun GH, Chen SY, et al: Pre-existing Fas ligand (FasL) in cancer cells elicits tumor-specific protective immunity, but delayed induction of FasL expression after inoculation facilitates tumor formation. Mol Carcinog. 52:705–714. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ardolino M, Azimi CS, Iannello A, et al: Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest. 124:4781–4794. 2014. View Article : Google Scholar : PubMed/NCBI
6	Mkrtichyan M, Ghochikyan A, Davtyan H, et al: Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol. 270:188–197. 2011. View Article : Google Scholar : PubMed/NCBI
7	Burdek M, Spranger S, Wilde S, et al: Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation. J Transl Med. 8:902010. View Article : Google Scholar : PubMed/NCBI
8	Parry AL, Clemson NA, Ellis J, et al: ‘Multicopy multivalent’ glycopolymer-stabilised gold nanoparticles as potential synthetic cancer vaccines. J Am Chem Soc. 135:9362–9365. 2013. View Article : Google Scholar : PubMed/NCBI
9	Hunn MK, Farrand KJ, Broadley KW, et al: Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma. Clin Cancer Res. 18:6446–6459. 2012. View Article : Google Scholar : PubMed/NCBI
10	Teitz-Tennenbaum S, Li Q, Davis MA and Chang AE: Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model. Clin Immunol. 129:482–491. 2008. View Article : Google Scholar : PubMed/NCBI
11	Chiang CL, Kandalaft LE, Tanyi J, et al: A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res. 19:4801–4815. 2013. View Article : Google Scholar : PubMed/NCBI
12	Obata C, Zhang M, Moroi Y, et al: Formalin-fixed tumor cells effectively induce antitumor immunity both in prophylactic and therapeutic conditions. J Dermatol Sci. 34:209–219. 2004. View Article : Google Scholar : PubMed/NCBI
13	Clay TM, Mosca PJ, Lyerly HK and Morse MA: Whole-tumor-cell vaccinesHandbook of Cancer Vaccines. Morse MA, Clay TM and Lyerly HK: Springer; pp. 249–251. 2004
14	Koido S, Homma S, Okamoto M, et al: Fusions between dendritic cells and whole tumor cells as anticancer vaccines. Oncoimmunology. 2:e244372013. View Article : Google Scholar : PubMed/NCBI
15	Yu P and Fu YX: Tumor-infiltrating T lymphocytes: friends or foes? Laboratory Invest. 86:231–245. 2006. View Article : Google Scholar
16	Sharma P, Shen Y, Wen S, et al: CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 104:3967–3972. 2007. View Article : Google Scholar : PubMed/NCBI
17	Clemente CG, Mihm MC Jr, Bufalino R, et al: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 77:1303–1310. 1996. View Article : Google Scholar : PubMed/NCBI
18	Aerts JG and Hegmans JP: Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res. 73:2381–2388. 2013. View Article : Google Scholar : PubMed/NCBI
19	Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850–854. 2002. View Article : Google Scholar : PubMed/NCBI
20	Sakaguchi S, Yamaguchi T, Nomura T and Ono M: Regulatory T cells and immune tolerance. Cell. 133:775–787. 2008. View Article : Google Scholar : PubMed/NCBI
21	Liu WK, Ho JC, Cheung FW, et al: Apoptotic activity of betulinic acid derivatives on murine melanoma B16 cell line. Eur J Pharmacol. 498:71–78. 2004. View Article : Google Scholar : PubMed/NCBI
22	Eggermont AM: Therapeutic vaccines in solid tumours: can they be harmful? Eur J Cancer. 45:2087–2090. 2009. View Article : Google Scholar : PubMed/NCBI
23	Pajtasz-Piasecka E and Indrová M: Dendritic cell-based vaccines for the therapy of experimental tumors. Immunotherapy. 2:257–268. 2010. View Article : Google Scholar : PubMed/NCBI
24	Hira SK, Mondal I and Manna PP: Combined immunotherapy with whole tumor lysate-pulsed interleukin-15-activated dendritic cells and cucurbitacin I promotes strong CD8(+) T-cell responses and cures highly aggressive lymphoma. Cytotherapy. 17:647–664. 2015. View Article : Google Scholar : PubMed/NCBI
25	Manzo T, Michelini RH, Sturmheit T, et al: Tumor-targeting vaccination instructs graft-vs.-tumor immune responses. Oncoimmunology. 2:e259962013. View Article : Google Scholar : PubMed/NCBI
26	Wu J, Fu W, Luo J and Zhang T: Expression and purification of human endostatin from Hansenula polymorpha A16. Protein Expr Purif. 42:12–19. 2005. View Article : Google Scholar : PubMed/NCBI
27	Kósa JP, Horváth P, Wölfling J, et al: CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells. World J Gastroenterol. 19:2621–2628. 2013. View Article : Google Scholar : PubMed/NCBI
28	Zamarron BF and Chen WJ: Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 7:651–658. 2011. View Article : Google Scholar : PubMed/NCBI